186763-78-0

Basic information

• Product Name: Ginsenoside-Rg5
• Synonyms: Ginsenoside-Rg5;(3beta,12beta,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside;Ginsenoside Rg5, 98%, from Panax ginseng C. A. Mey.
• CAS NO: 186763-78-0
• Molecular Formula: C41H68O12
• Molecular Weight: 752.97142
• Mol File: 186763-78-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 859.7°C at 760 mmHg
• Flash Point: 473.7°C
• Appearance: /
• Density: 1.28±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1.93E-34mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C
• PKA: 12.85±0.70(Predicted)
• CAS DataBase Reference: Ginsenoside-Rg5(CAS DataBase Reference)
• NIST Chemistry Reference: Ginsenoside-Rg5(186763-78-0)
• EPA Substance Registry System: Ginsenoside-Rg5(186763-78-0)

Safety Data

• Hazardous Substances Data: 186763-78-0(Hazardous Substances Data)

Usage

Description

Ginsenoside-Rg5 is a natural product derived from Panax japonicus var. major, specifically from the leaves of the Panax ginseng plant. It is known for its potential medicinal properties and is currently being studied for its various applications in the field of healthcare.

Uses

Used in Pharmaceutical Industry:
Ginsenoside-Rg5 is used as an aromatase inhibitor for the treatment of conditions related to hormonal imbalances. Aromatase is an enzyme that plays a crucial role in the production of estrogen, and its inhibition can be beneficial in managing certain health issues.
Used in Oncology:
Ginsenoside-Rg5 is used as a potential therapeutic agent in oncology, particularly for the treatment of various types of cancer. Its ability to inhibit aromatase may contribute to the suppression of tumor growth and progression, making it a promising candidate for further research and development in cancer treatment.
Used in Nephrotoxicity Treatment:
Ginsenoside-Rg5 is used as a nephroprotective agent to ameliorate cisplatin-induced nephrotoxicity in mice. Cisplatin is a widely used chemotherapy drug, but its use can lead to kidney damage due to its toxic effects. Ginsenoside-Rg5 has shown potential in reducing inflammation, oxidative stress, and apoptosis associated with cisplatin-induced nephrotoxicity, offering a possible solution to minimize the side effects of this chemotherapy drug.

InChI:InChI=1/C42H70O12/c1-20(2)10-9-11-21(3)23-12-14-42(8)30-22(4)16-28-40(5,6)29(13-15-41(28,7)24(30)17-25(45)31(23)42)53-39-37(35(49)33(47)27(19-44)52-39)54-38-36(50)34(48)32(46)26(18-43)51-38/h10-11,22-39,43-50H,9,12-19H2,1-8H3/b21-11+/t22?,23-,24?,25+,26-,27-,28?,29?,30?,31?,32-,33-,34+,35+,36-,37-,38+,39+,41-,42-/m1/s1

Upstream product

• 41753-43-9 Ginsenoside Rb₁ 
• 38243-03-7 20(R)-ginsenoside Rg₃ 
• 126252-51-5 (3β,12β,20R/20S)-12,20-dihydroxydammar-24-en-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside 

Relevant articles and documents

The preparation of ginsenoside Rg5, its antitumor activity against breast cancer cells and its targeting of PI3K

Ginsenosides have been reported to possess various pharmacological effects, including anticancer effects. Nevertheless, there are few reports about the antitumor activity and mechanisms of ginsenoside Rg5 against breast cancer cells. In the present study, the major ginsenoside Rb1 was transformed into the rare ginsenoside Rg5 through enzymatic bioconversion and successive acid-assisted high temperature and pressure processing. Ginsenosides Rb1, Rg3, and Rg5 were investigated for their antitumor effects against five human cancer cell lines via the MTT assay. Among them, Rg5 exhibited the greatest cytotoxicity against breast cancer. Moreover, Rg5 remarkably suppressed breast cancer cell proliferation through mitochondria-mediated apoptosis and autophagic cell death. LC3B-GFP/Lysotracker and mRFP-EGFP-LC3B were utilized to show that Rg5 induced autophagosome-lysosome fusion. Western blot assays further illustrated that Rg5 decreased the phosphorylation levels of PI3K, Akt, mTOR, and Bad and suppressed the PI3K/Akt signaling pathway in breast cancer. Moreover, Rg5-induced apoptosis and autophagy could be dramatically strengthened by the PI3K/Akt inhibitor LY294002. Finally, a molecular docking study demonstrated that Rg5 could bind to the active pocket of PI3K. Collectively, our results revealed that Rg5 could be a potential therapeutic agent for breast cancer treatment.

Blank mixed micelle, and preparation method and applications thereof

The invention discloses blank mixed micelle, and a preparation method and applications thereof. The blank mixed micelle comprises an amphiphilic copolymer and ginsenoside represented by formula I, ishigh in efficiency, is safe, is stable, is high in targeting performance, is excellent in homogeneity, is stable in quality, is convention in preparation technology, can be used for coating one or a plurality of active substances in drugs or cosmetics and health care substances, and is capable of forming mixed micelle containing loaded active substances. Compared with conventional nanometer micelle, the blank mixed micelle possesses following advantages: the mixed micelle loaded with active substances is excellent in drug forming performance, multiple drug resistance, stability, homogeneity, and safety performance, and is small in particle size; and the curative effect of loaded active drugs on drug resistant cells is better.